TokenPost·
GSK Q3 Sales Rise 4% as Core EPS Beats Consensus by 4.2 Pence
Specialty Medicines sales grew 15% at constant exchange rates, and GSK reaffirmed its 2026 outlook.
More news
- TokenPostFred Krueger Proposes a $2 Million Bitcoin Wager to Jason Calacanis
- TokenPostAena Passenger Traffic Rises 4.1% to 309.9 Million Through September
- TokenPostLarge Bitcoin Orders Recede Ahead of Federal Open Market Committee Meeting
- TokenPostFujifilm Plans ¥10 Billion Tape Expansion for AI Data Demand
- CryptoPotatoOutpoll Trading: Bridging Crypto, Stocks, Indices, and Commodities
- CryptopolitanCoinbase customer contact data caught in analytics vendor Amplitude's security incident